After Biohaven announced that the Phase II/III trial of troriluzole for the treatment of generalized anxiety disorder, or GAD, failed to meet its primary endpoint, William Blair analyst Tim Lugo called the news "disappointing," but added that he always saw this as a high-risk trial given the lack of prior clinical data in the GAD indication. The analyst, who continues to sees the focus for Biohaven as the upcoming readout from the Phase 3 prevention study of migraine and a PDUFA date for rimegepant for the treatment of acute migraine, maintains his Outperform rating on the shares given his view that rimegepant is a best-in-class oral CGRP antagonist.